Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal polysaccharide vaccine group Y
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal polysaccharide vaccine group Y refers to the purified capsular polysaccharide antigen extracted from Neisseria meningitidis serogroup Y. This polysaccharide acts as an immunogen, stimulating the human immune system to produce specific antibodies against Neisseria meningitidis serogroup Y. It is a key component in various meningococcal vaccines, particularly quadrivalent (MenACWY) and pentavalent (MenABCWY) conjugate vaccines, which combine polysaccharides from multiple serogroups (A, C, W, Y, and sometimes B) with a carrier protein to enhance immunogenicity and provide broader protection against invasive meningococcal disease, including meningitis and septicemia. These vaccines are designed to prevent infections caused by Neisseria meningitidis serogroup Y.
- Other names
- Meningococcal group Y polysaccharide
02
Targets
Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on Meningococcal polysaccharide vaccine group Y.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal polysaccharide vaccine group Y.